ABSTRACT
Introduction: Due to the COVID-19 pandemic, health systems have had to adapt to the growing demand for care. Telemedicine is a practical tool for outpatient monitoring of correctly selected patients. Materials and Methods: A descriptive study of a prospective cohort of patients under telemedicine follow-up at the Hospital Italiano de San Justo was carried out. Results: 47 days of follow-up were evaluated, a total of 1345 patients. Of these, 46.9% (n = 631) obtained a positive nasopharyngeal swab result with PCR technique and were registered in the telemedicine monitoring system, with 10.14% (n = 64) requiring a new clinical evaluation at the emergency center . Of these patients, 60.1% (n = 39) required hospitalization in a general ward (n = 39). Conclusion: It is essential to be able to generate other forms of helth care. The telemedicine system is an important tool to develop in situations of overload of the health system.
Introducción: Debido a la pandemia por COVID-19 los sistemas sanitarios han tenido que adaptarse a la demanda asistencial. La telemedicina es una herramienta práctica para poder realizar seguimiento ambulatorio de pacientes correctamente seleccionados. Materiales y Métodos: Se realizó un estudio descriptivo de una cohorte prospectiva de pacientes en seguimiento por telemedicina en el Hospital Italiano de San Justo. Resultados: Se evaluaron 47 días de seguimiento, un total de 1345 pacientes. De éstos 46,9% (n=631) obtuvieron un resultado de hisopado nasofaríngeo con técnica de PCR positivo y fueron ingresados al sistema de seguimiento por telemedicina. El 10,14% (n=64) requirió una reevaluación clínica en guardia externa. De estos pacientes el 60.1% (n=39) requirió internación en sala general (n=39). Conclusión: Es fundamental poder generar otras formas de cuidado de la salud. El sistema de telemedicina es una herramienta importante a desarrollar en situaciones de sobrecarga del sistema de salud.
Subject(s)
COVID-19/diagnosis , Telemedicine , Argentina , Follow-Up Studies , Hospitals , Humans , Pandemics , Prospective StudiesABSTRACT
BACKGROUND: Convalescent plasma is frequently administered to patients with Covid-19 and has been reported, largely on the basis of observational data, to improve clinical outcomes. Minimal data are available from adequately powered randomized, controlled trials. METHODS: We randomly assigned hospitalized adult patients with severe Covid-19 pneumonia in a 2:1 ratio to receive convalescent plasma or placebo. The primary outcome was the patient's clinical status 30 days after the intervention, as measured on a six-point ordinal scale ranging from total recovery to death. RESULTS: A total of 228 patients were assigned to receive convalescent plasma and 105 to receive placebo. The median time from the onset of symptoms to enrollment in the trial was 8 days (interquartile range, 5 to 10), and hypoxemia was the most frequent severity criterion for enrollment. The infused convalescent plasma had a median titer of 1:3200 of total SARS-CoV-2 antibodies (interquartile range, 1:800 to 1:3200). No patients were lost to follow-up. At day 30 day, no significant difference was noted between the convalescent plasma group and the placebo group in the distribution of clinical outcomes according to the ordinal scale (odds ratio, 0.83; 95% confidence interval [CI], 0.52 to 1.35; P = 0.46). Overall mortality was 10.96% in the convalescent plasma group and 11.43% in the placebo group, for a risk difference of -0.46 percentage points (95% CI, -7.8 to 6.8). Total SARS-CoV-2 antibody titers tended to be higher in the convalescent plasma group at day 2 after the intervention. Adverse events and serious adverse events were similar in the two groups. CONCLUSIONS: No significant differences were observed in clinical status or overall mortality between patients treated with convalescent plasma and those who received placebo. (PlasmAr ClinicalTrials.gov number, NCT04383535.).